

DEAV2002/0049 US NP

PATENT

REMARKS

Upon entry of Applicants' RCE and the foregoing amendments, claims 1 to 29 will be pending in this patent application. Claim 1 has been amended. Claims 18 to 29 are new. Support for the amendment to claim 1 is found throughout Applicants' specification such as, for example, at page 6, paragraph [025]; page 9, paragraph [056]; page 10, paragraph [061] to page 11, paragraph [066]; and original claim 1.

Support for new claim 18 is found in Applicants' specification at, for example, page 41, paragraph [0183].

Support for new claims 19 to 29 is found throughout Applicants' specification such as, for example, in the working Examples. In this regard, claim 19 recites all of the exemplified compounds; claim 20 recites the compounds of Examples 7, 9, 11, 13, 20, 31, 34, 43, 45, and 54; and claims 20 to 29 individually recite the compounds of Examples 7, 9, 11, 13, 20, 31, 34, 43, 45, and 54, respectively.

Paragraph [058] was amended to add the word "glycoside" to modify the sugar residues in the compounds of formula I. Such amendment is supported throughout Applicants' specification, which is directed to substituted thiophene *glycoside* derivatives.

Paragraph [0108] was amended to correct a typographical error in an alphabetical reference to a chemical compound illustrated in a schematic figure. Support for this amendment is found in Applicants' specification at, for example, page 21 (Process D).

Paragraph [0221] was amended to add the obvious missing reactant. Support for the addition of "along with the reactant 4-methyl-styrene" is found at, for example, the schematic figure on page 58, as well as on paragraph [098] on page 20 of Applicants' specification. Accordingly, no new matter has been added.

With the foregoing amendments, Applicants have also amended the specification to include a specific reference claiming the benefit under 35 U.S.C. § 119(e) of the earlier filing

DEAV2002/0049 US NP

PATENT

date of U.S. provisional patent application No. 60/425,684, filed November 12, 2002 ("the 684 application"). The present application was filed within twelve (12) months from the filing date of the 684 application.


Applicants further note that, by the foregoing amendment to paragraph [001], they are *not* disclaiming priority benefit to German Patent Application Number 10231370.9-43, filed on July 11, 2002 ("the German priority document"). Such priority was properly perfected by reference in Applicants' signed Combined Declaration for Patent Application and Power of Attorney, filed on January 26, 2004, as well as with the receipt of the certified copy of the priority document as acknowledged in the Office Action dated February 2, 2005. The sole purpose of the amendment to delete the reference to the German priority document is to place the cross-reference section of the present application into better compliance with U.S. patent practice.

Applicants respectfully submit that, in view of the foregoing amendments, the claims remain in condition for allowance. If there are any issues that can be resolved by a telephone conference or an Examiner's amendment, the Examiner is invited to call the undersigned attorney at (908) 231-3410.

The Commissioner is hereby authorized to charge the fee required and any additional fees that may be needed to Deposit Account No. 18-1982 in the name of Aventis Pharmaceuticals Inc.

Respectfully submitted,

Dated: August 24, 2005



Joseph D. Rossi
Registration No. 47,038
Attorney for Applicants

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800

AUG. 24. 2005 2:37PM AVENTIS US PAT DEPT

NO. 7746 P. 23

DEAV2002/0049 US NP

PATENT

Telephone: 908-231-3410
Telefax: 908-231-2626

Aventis Docket No. DEAV2002/0049 US NP